Protagenic Therapeutics completes enrollment, dosing in Phase 1 MAD study

Protagenic Therapeutics (PTIX) announced the completion of enrollment and dosing in its Multiple Ascending Dose Phase 1 study evaluating its lead compound, known as PT00114. The study, conducted in healthy volunteers, was designed to assess the safety and tolerability profile of PT00114 following multiple doses over time. With all healthy volunteers now dosed, the company has achieved a milestone in the clinical development of its proprietary peptide-based therapeutic. The company expects to finalize and release top-line results from the MAD study by November 30.